Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146795 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Therapy for Ovarian Cancer
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Jason D. Wright.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT01146795 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by Jason D. Wright. The registered enrollment target is 32 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01146795, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by Jason D. Wright.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. This study will also investigate the rate of optimal cytoreduction, response rate and progression free and overall survival, and to assess the quality of life for patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer treated with neoadjuvant carboplatin, paclitaxel and bevacizumab.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
Study Locations (3)
New York
- Columbia University Medical Center - New York
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-05-17 |
| Est. Completion | 2015-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146795
The ClinicalTrials.gov registry entry for NCT01146795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Jason D. Wright, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01146795 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Pennsylvania, Virginia.
Frequently Asked Questions
What is clinical trial NCT01146795 about?
NCT01146795 is a clinical study titled "Neoadjuvant Therapy for Ovarian Cancer". This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. This study will also investigate the rat...
What is the current status of trial NCT01146795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2010-05-17. Estimated completion is 2015-04-13.
What conditions does trial NCT01146795 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT01146795?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01146795?
This trial is sponsored by Jason D. Wright, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01146795 being conducted?
This trial has 3 study locations across New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.